

## Thursday, September 22, 2011

### Introductions

- 8:30 Robert Wiltout  
8:45 Steven Rosenberg

### Session 1: T-cell Transfer Immunotherapy

**Chair: Steven Rosenberg**

- 9:00 Steven Rosenberg  
*Regression of metastatic cancer in humans mediated by adoptive T-cell transfer*
- 9:30 Nicholas Restifo  
*Principles of immunotherapy as elucidated in animal models*
- 10:00 Patrick Hwu  
*Current status and future directions of melanoma T-cell therapy at MD Anderson Cancer Center*
- 10:30 **BREAK**
- 11:00 Malcolm Brenner  
*Breaking the barriers for T-cell immunotherapy*
- 11:30 Ton Schumacher  
*Dissecting therapy-induced T-cell responses in melanoma*
- 12:00 Jacob Schachter  
*Adoptive cell therapy of metastatic melanoma using “young” TIL*
- 12:30 **LUNCH and POSTER VIEWING**

### Session 2: Immunotherapy Based on Genetic Engineering of Lymphocytes

**Chair: James Yang**

- 1:30 Antoni Ribas  
*TCR engineering adoptive cell transfer guided by molecular imaging and nanodiagnostics*
- 2:00 Michel Sadelain  
*Targeting tumors with genetically enhanced T lymphocytes*

- 2:30 Stanley Riddell  
*Immunotherapy of leukemia after allogeneic cell transplant*
- 3:00 **BREAK**
- 3:30 Michael Jensen  
*Insights from CAR-redirected T-cell clinical trials*
- 4:00 Carl June  
*Adoptive therapy with lentiviral T cells for cancer: Lessons from pilot trials*
- 4:30 Jeffrey Miller  
*Manipulating NK cells to fight cancer*
- 5:00 **ADJOURN and POSTER VIEWING**

## Friday, September 23, 2011

### Session 3: Vaccine-Based Therapies

**Chair: Jeffrey Schlom**

- 8:30 Jeffrey Schlom  
*Vector-based vaccines for prostate and colorectal cancers*
- 9:00 Cornelius Melief  
*Peptide vaccine for vulvar intraepithelial neoplasia*
- 9:30 Mary Disis  
*Epitope-based vaccines for breast cancer*
- 10:00 Jay Berzofsky  
*Dendritic cell-based vaccines for cancer: Epitope enhancement and blockade of negative regulation*
- 10:30 **BREAK**

### Session 4: Transplantation-Based Therapies

**Chair: Ronald Gress**

- 11:00 Ronald Gress  
*T-cell homeostasis and immunotherapy*
- 11:30 Daniel Fowler  
*Allogeneic immunotherapy using rapamycin-resistant cells*
- 12:00 Catherine Bollard  
*Broadening virus-specific T-cell therapy applications for patients after stem cell transplant*
- 12:30 **LUNCH and POSTER VIEWING**
- 1:30 Marcel van den Brink  
*Tipping the balance from graft-versus-host disease to graft-versus-tumor activity after allogeneic bone marrow transplantation*
- 2:00 Crystal Mackall  
*Adoptive NK cell therapy in the setting of allogeneic stem cell transplantation*

## **Session 5: Immune-Modulatory Approaches**

**Chair: Thomas Waldmann**

- 2:30 Jedd Wolchok  
*Update on clinical and correlative immunologic results using CTLA-4 blockade for melanoma*
- 3:00 Thomas Waldmann  
*Optimizing IL-15 treatment of metastatic malignancy*
- 3:30 **BREAK**
- 4:00 Ira Pastan  
*Recombinant immunotoxins in the 21st century*
- 4:30 Suzanne Topalian  
*Targeting the PD-1/B7-H1 axis in cancer immunotherapy*
- 5:00 **ADJOURN**